

BIO Elects New Chairman of the Board

Also Announces New 2011–2012 Executive Committee and Board Members

For Immediate Release

6/28/2011

Contact:

Contact Abigail Hirsch
202-962-9235

WASHINGTON, D.C. (Tuesday, June 28, 2011) - The Biotechnology Industry Organization (BIO) is pleased to announce the election of H. Thomas Watkins, President & CEO of Human Genome Sciences, Inc, as its new Chairman of the Board for the 2011-2012 term. BIO also is pleased to announce the election of 18 Directors on its Board to serve on BIO's Executive Committee for the new term, as well as the election of 23 new members to its Board of Directors, voted upon at this year's 2011 BIO International Convention.

"Tom Watkins brings a depth of industry experience and passion for advocacy that will serve BIO and its members well during his chairmanship of our organization," said Jim Greenwood, BIO President & CEO. "I look forward to working closely with Tom and our newly-constituted Board of Directors to build on BIO's record of success in the years to come." Greenwood noted that Watkins' company Human Genome Sciences, Inc, recently obtained FDA approval for the first new drug in 56 years to treat lupus, a serious and potentially fatal autoimmune disease that attacks healthy tissues. "Tom knows first-hand what it takes to successfully innovate in today's financial and regulatory climate, and will be a major asset to BIO as we seek to improve the policy environment for our member companies," he said.

Greenwood added, "I also welcome our new Board members and know that the contributions they will make to both the industry and within BIO will be substantial. The new Directors bring a wealth of expertise and diversity in experience that will help contribute to the continued growth of BIO as a membership organization."

Greenwood also thanked BIO's departing Board members. "BIO is deeply appreciative to departing Board members for their service," said Greenwood. "I want to especially thank our outgoing Board Chairman, Dr. Steve Sherwin, for his dedication and valuable service to BIO over the past decade, and especially the last two years as BIO's Chairman. As a practicing medical oncologist, Steve brought a special patient-focused perspective to BIO's policy development and advocacy, never letting us forget why we in this industry do what we do. While he is stepping down as Chair, I am pleased that Steve will remain a leader on our Board."

Members of the Executive Committee of BIO's Board of Directors for the 2011-2012 term are:

Joshua Boger, At Large
Founder and Member of the Board, Vertex Pharmaceuticals Incorporated

Fabrizio Bonanni, Board Secretary
Executive Vice President, Operations, Amgen, Inc

Ian Clark, At Large
CEO & Head of North American Commercial Operations, Genentech, Roche

Ron Cohen, Emerging Companies Section Chair
President & CEO, Acorda Therapeutics, Inc

Tjerk de Ruiter, Industrial & Environmental Section Chair
Chief Executive Officer, Genecor: Danisco A/S

Douglas Doerfler, At Large
President & CEO, MaxCyte, Inc

Deborah Dunsire, At Large
President & CEO, Millennium: The Takeda Oncology Company

Paul Hastings, Emerging Companies Section Vice Chair
President & CEO, OncoMed Pharmaceuticals, Inc

Rachel King, Health Section Vice Chair
President & CEO, GlycoMimetics, Inc

Adam Monroe, Industrial and Environmental Section Vice Chair
President, Novozymes North America

Richard Pops, At Large
Chairman, President & CEO, Alkermes, Inc

David Pyott, At Large
Chairman & CEO, Allergan, Inc

Stephen Sherwin, Board Immediate Past Chair
Chair Emeritus

Jay Siegel, At Large
Chief Biotechnology Officer & Head of Global Regulatory Affairs, Johnson and Johnson

Mark Skaletsky, Board Treasurer
Chairman, NeuroPhage Pharmaceuticals, Inc

Gerald Steiner, Food & Agriculture Section Vice Chair
Executive Vice President, Sustainability & Corporate Affairs, Monsanto Company

H. Thomas Watkins, Board & Health Section Chair
President & CEO, Human Genome Sciences, Inc

Barbara Wells, Food & Agriculture Section Chair
President & CEO, ArborGen, LLC

The full BIO Board of Directors is comprised of the elected Directors serving on each of BIO's Section Governing Boards (Health, Emerging Companies, Industrial & Environmental, and Food & Agriculture). The newly-elected Board Members from these Sections are:

Emerging Companies Section Governing Board

- Brian Atwood, Managing Director, Versant Ventures
- Robert Beall , President & CEO, Cystic Fibrosis Foundation
- Glen Giovanetti , Global Biotechnology Leader, Ernst & Young
- Barbara Kosacz , Partner, Cooley, LLP
- Edward Mathers, Partner, New Enterprise Associates, Inc
- John Orwin , Chief Executive Officer, Affymax, Inc

Food and Agriculture Section Governing Board

- Bruce Ferguson, Chairman, President & CEO, Edenspace
- Jerry Flint, Senior Director of Biotechnology Regulatory Affairs, Pioneer/DuPont
- Matthias Kremer, Head of BioScience, Bayer CropScience
- Robin Readnour, Senior Director of Product Development, Elanco Animal Health
- Ralf-Michael Schmidt, Vice-President, BASF Group; Global Head of BASF Plant Sciences Government, BASF

Health Section Governing Board

- Donald Beeman, Chief Executive Officer, LigoCyte Pharmaceuticals, Inc
- Steven Holtzman, Executive Vice President, Corporate Development, Biogen Idec
- James Manuso, President & CEO, SuperGen, Inc
- Julie McHugh, Chief Operating Officer, Endo Pharmaceuticals
- Vincent Milano, President, CEO & Chairman of the Board of Directors, ViroPharma Incorporated
- Steven Nichtberger, President & CEO, Tengion, Inc
- Arthur Sands, President & CEO, Lexicon Pharmaceuticals, Inc
- Daniel Tassé, Chairman & CEO, Ikaria, Inc
- Roland Turck, Head of Global Strategic Marketing Specialty Medicine, Bayer Healthcare AG